WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · HB 3430

Bill Overview

HB 3430 (Missouri, 2026) establishes a Sickle Cell Standing Committee within the Department of Health and Senior Services (DHSS). The bill aims to create a formal, ongoing body to advise on policy, program development, and coordination related to sickle cell disease (SCD) and related health issues.

Purpose and Intent

  • Create a standing committee dedicated to sickle cell disease under DHSS.
  • Provide ongoing guidance to state health policy, public health programs, research, and services affecting individuals with SCD.
  • Improve coordination across agencies and stakeholders to address SCD-related health needs, disparities, and access to care.

Key Provisions and Changes

  • Establishment of the Sickle Cell Standing Committee within DHSS.
  • Likely membership structure (e.g., representation from public health, clinical professionals, patient advocates, community organizations, and affected individuals), though specific composition is not detailed in the summary.
  • Authorization for the committee to advise on:
    • Development and oversight of SCD-related public health initiatives.
    • Data collection, surveillance, and reporting on SCD incidence, outcomes, and disparities.
    • Education, outreach, and awareness campaigns.
    • Access to quality care, newborn screening, and preventive services.
    • Allocation or guidance on state resources and potential grant opportunities related to SCD.
    • Coordination with hospitals, clinics, and social services to address comprehensive care needs.
  • Potential duties for DHSS, including implementation of committee recommendations and regular reporting to the General Assembly or relevant oversight bodies.
  • Any procedural requirements for the committee’s operation (e.g., meeting cadence, reporting deadlines, duration of terms for members) are not specified in the provided summary but would be expected in the bill text.

Who is Affected

  • Individuals with sickle cell disease and their families, who may benefit from enhanced policy attention, improved access to care, and targeted state programs.
  • Healthcare providers, public health professionals, and researchers involved in SCD-related care, surveillance, and education.
  • Hospitals, clinics, and public health departments collaborating with DHSS on SCD initiatives.
  • State agencies that interact with DHSS for related health services and data reporting.

Procedural and Timeline Aspects

  • Introduction: February 25, 2026.
  • Second Reading: February 26, 2026.
  • Referral: Emerging Issues (H) on May 15, 2026.
  • As a newly established standing committee, the bill would typically require routine meetings, a charter or bylaws, and periodic reporting. Specific timelines (e.g., initial appointment periods, reporting deadlines, and terms of service) would be defined in the enacted text.

Additional Notes

  • Co-sponsors: Tiffany Price and Kem Smith.
  • The summary does not provide detailed provisions on funding, appointment processes, or the exact scope of authority; the enacted bill text would clarify membership, duties, and reporting requirements.
  • The bill reflects an emphasis on structured governance to address sickle cell disease within Missouri’s public health framework.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.